Who
William D. Humphries
Director
Company insider
Files Form 4 as: Director, Aclaris Therapeutics; Director, Clearside Biomedical; Director, STRATA Skin Sciences; Director, PhaseBio Pharmaceuticals; President, Ortho-Dermatologics, Bausch Health Companies.
In numbers
- Trades disclosed
- 94
- Buys
- 4
- Sells
- 5
- Bought
- $713K
- Sold
- $3.1M
- Companies
- 5
- Companies where not an officer
- 4
- First trade
- 1 Sep 2016
- Last trade
- 5 Jun 2026
- Last filed
- 8 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 5 Jun 2026filed 8 Jun 2026 | ACRS Aclaris TherapeuticsBiotechnology | SEC FORM 4 Code M | —11,580 | filing |
| 5 Jun 2026filed 8 Jun 2026 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —11,580 at $0.00 | filing |
| 5 Jun 2026filed 8 Jun 2026 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —11,580 at $0.00 | filing |
| 5 Jun 2026filed 8 Jun 2026 | ACRS Aclaris TherapeuticsBiotechnology | SEC FORM 4 Code M | —11,580 | filing |
| 4 Jun 2026filed 8 Jun 2026 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —42,350 at $0.00 | filing |
| 4 Jun 2026filed 8 Jun 2026 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,987 at $0.00 | filing |
| 4 Jun 2026filed 8 Jun 2026 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —42,350 at $0.00 | filing |
| 4 Jun 2026filed 8 Jun 2026 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,987 at $0.00 | filing |
| 6 Jun 2025filed 9 Jun 2025 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —4,793 at $0.00 | filing |
| 6 Jun 2025filed 9 Jun 2025 | ACRS Aclaris TherapeuticsBiotechnology | SEC FORM 4 Code M | —4,793 | filing |
| 5 Jun 2025filed 9 Jun 2025 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —42,350 at $0.00 | filing |
| 5 Jun 2025filed 9 Jun 2025 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,580 at $0.00 | filing |
| 20 Jun 2024filed 21 Jun 2024 | Clearside Biomedicaloption or derivative | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 6 Jun 2024filed 10 Jun 2024 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,750 at $0.00 | filing |
| 6 Jun 2024filed 10 Jun 2024 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,793 at $0.00 | filing |
| 1 Jun 2024filed 4 Jun 2024 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —4,660 at $0.00 | filing |
| 1 Jun 2024filed 4 Jun 2024 | ACRS Aclaris TherapeuticsBiotechnology | SEC FORM 4 Code M | —4,660 | filing |
| 22 Sep 2023filed 22 Sep 2023 | Clearside Biomedicaloption or derivative | SEC FORM 4 Code M | —22,727 at $0.00 | filing |
| 22 Sep 2023filed 22 Sep 2023 | Clearside Biomedical | SEC FORM 4 Code M | $9,09122,727 at $0.40 | filing |
| 5 Jul 2023filed 7 Jul 2023 | STRATA Skin Sciences | SEC FORM 4 Code A | $38K36,408 at $1.03 | filing |
News
Contrasting Ocular Therapeutix (NASDAQ:OCUL) and Bausch Health Cos (NYSE:BHC)BHC · dailypolitical.com · 13 Oct 2026Contrasting Bausch Health Cos (NYSE:BHC) and Journey Medical (NASDAQ:DERM)BHC · themarketsdaily.com · 8 Oct 2026
0 headlines in the last 90 days name William D. Humphries; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.